Shattuck Labs, Inc.
STTK
$-0.09
Change (1 day)
$11.76
Year High
$1.02
Year Low
Categories
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. (STTK) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -121,424,000 | 14.86 M | 159.56 M | 143.22 M | |
| 2022 | -43,177,000 | 29.17 M | 205.32 M | 184.58 M | |
| 2021 | -92,268,000 | 26.8 M | 298.59 M | 288.27 M | |
| 2020 | -157,898,000 | 39.13 M | 348.99 M | 345.64 M | |
| 2019 | -7,013,000 | 79.52 M | 44.97 M | 42.44 M |